Supplemental material

Abbreviations:

CPT, camptothecin; CTD, C-terminal domain; DRB, 5,6-dicholoro-1-β-D-ribobenzimidazole; DSBs, double-strand breaks; etoposide, 4'-demethylepipodophyllotoxin ethylidene-β-Dglucoside; pMEFs, primary mouse embryonic fibroblasts; MG132: carbobenzoxy-L-leucyl-Lleucyl-L-leucinal; RNAPII, RNA polymerase II; RNAPII LS, the large subunit of RNA polymerase II; Ser2-P, serine-2 phosphorylated; Ser5-P, serine-5 phosphorylated; SSB, singlestrand breaks; t-AML, therapy-related acute myeloid leukemia; Top1, topoisomerase I; Top2, topoisomerase II; Ub, ubiquitin.

Supplemental Figure Legend

Fig. S1 (A) Over-expression of UBA domain of Rad23 (ΔUBL) did not abolish VP-16-induced Top2β degradation. HeLa cells were transfected with the plasmid (pcDNA3) expressing truncated Rad23 ΔUBA or ΔUBL. Empty vector served as a vehicle control. Cells were then treated with 250 μ M VP-16 or 25 μ M CPT for time periods as indicated. Cell lysates were prepared and immunoblotted with anti-Top1, Top2β or α-tubulin antibody. CPT-induced Top1 degradation served as positive control for Ub-dependent degradation (24). (**B**) siRNA-mediated silencing of PA28γ regulatory particle does not impact VP-16-induced degradation of Top2β. HeLa cells were transfected with control or PA28γ siRNA. 72 hrs post-transfection, cells were treated with 250 μ M VP16 or 25 μ M CPT in the presence or absence of proteasome inhibitor MG132 for time periods as indicated. Cell lysates were immunoblotted with anti-Top1, Top2β or α-tubulin antibody. Silencing of PA28γ protein. **Fig. S2** (**A**) The knockdown efficiencies of 19S siRNAs were evaluated by the decrease of its corresponding protein. HeLa cells were transfected with control, Rpt5, Rpt6, Rpn2, Rpn11or S5a siRNA. 72 hrs post-transfection, cell lysates were immunoblotted with anti-Rpt5, Rpt6, Rpn2, Rpn11or S5a antibody. (**B**) The knockdown efficiencies of 19S siRNAs were further confirmed by the accumulation of Ub-conjugates in whole cell lysates. HeLa cells were transfected with control, Rpt5, Rpt6, Rpn2, Rpn11or S5a siRNA. 72 hrs post-transfected with same protein concentration were immunoblotted with anti-Ub antibody.

Fig. S3 A model that schematically depicts the two different polarities of the Top1 roadblock and the subsequent responses of RNAPII.